Litcius/Paper detail

Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18–26 years in China: a randomised blinded clinical trial

Fengcai Zhu, Guo‐Hua Zhong, Weijin Huang, Kai Chu, Li Zhang, Zhaofeng Bi, Kongxin Zhu, Qi Chen, Tingquan Zheng, Minglei Zhang, Sheng Liu, Jin‐Bo Xu, Hongxing Pan, Guang Sun, Feng-Zhu Zheng, Qiu-Fen Zhang, Xiu-Mei Yi, Sijie Zhuang, Shoujie Huang, Huirong Pan, Yingying Su, Ting Wu, Jun Zhang, Ningshao Xia

2023The Lancet Infectious Diseases41 citationsDOI

Topics & Concepts

GardasilMedicineSeroconversionImmunogenicityHPV vaccinesHuman papillomavirus vaccineVaccinationClinical trialInternal medicineVirologyHPV infectionCervical cancerImmunologyAntibodyVirusCancerCervical Cancer and HPV ResearchImmunotherapy and Immune ResponsesHerpesvirus Infections and Treatments